Etrasimod arginine - Generic Drug Details

What are the generic drug sources for etrasimod arginine and what is the scope of freedom to operate?

Etrasimod arginine is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etrasimod arginine has one hundred and thirty-one patent family members in thirty countries.

Two suppliers are listed for this compound.

Summary for etrasimod arginine

International Patents:	131
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Patent Applications:	11
DailyMed Link:	etrasimod arginine at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for etrasimod arginine

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for etrasimod arginine

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Anatomical Therapeutic Chemical (ATC) Classes for etrasimod arginine

L04AE	Sphingosine-1-phosphate (S1P) receptor modulators
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for etrasimod arginine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes			Y	Y
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes			Y	Y

International Patents for etrasimod arginine

Country	Patent Number	Title	Estimated Expiration
France	24C1031
Denmark	2326621
China	104311472

Supplementary Protection Certificates for etrasimod arginine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2326621	C02326621/01	Switzerland		PRODUCT NAME: ETRASIMOD, TEL QUE L'ETRASIMOD ARGININE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69377 10.09.2024
2326621	301284	Netherlands		PRODUCT NAME: ETRASIMOD, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ETRASIMOD ARGININE; REGISTRATION NO/DATE: EU/1/23/1790 20240219
2326621	2490310-6	Sweden		PRODUCT NAME: ETRASIMOD, ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV, SASOM ETRASIMODARGININ; REG. NO/DATE: EU/1/23/1790 20240219

Market Dynamics and Financial Trajectory for Etrasimod Arginine

Last updated: January 14, 2026

Summary

Etrasimod Arginine, a selective sphingosine-1-phosphate receptor (S1P) modulator, is an investigational drug primarily targeting immune-mediated disorders such as ulcerative colitis, Crohn's disease, and atopic dermatitis. The drug's innovative mechanism of action, coupled with its promising clinical trial data, positions it as a potential blockbuster in the expanding immunomodulatory therapeutic market. This comprehensive analysis delineates the current market dynamics, anticipated financial trajectory, competitive landscape, regulatory considerations, and strategic implications for stakeholders interested in Etrasimod Arginine.

---

What Is Etrasimod Arginine and Its Development Status?

Etrasimod Arginine is a combination of etrasimod, a selective S1P receptor modulator, and arginine, a amino acid linked to immune modulation. Developed by Arena Pharmaceuticals (acquired by Pfizer in 2022), its clinical pipeline primarily targets immune-mediated diseases with high unmet needs.

Development Phases

Phase	Indications	Status	Key Data	Expected Approval Timeline
Phase 2	Ulcerative Colitis, Crohn's Disease	Completed	Positive efficacy and safety signals in Phase 2 (2019–2021)	2023–2024 (FDA/EMA submissions)
Phase 3	Ulcerative Colitis, Atopic Dermatitis	Ongoing	Topline data projected for 2023	2024–2025 (Regulatory filing)
Preclinical	Additional indications	Active	Promising preclinical efficacy	N/A

Source: Arena Pharmaceuticals Clinical Trial Registry, 2023[1]

---

What Are the Key Market Drivers for Etrasimod Arginine?

1. Rising Prevalence of Autoimmune Diseases

Global autoimmune disease prevalence has increased, with ulcerative colitis affecting approximately 1.3 million Americans, Crohn's disease approximately 800,000, and atopic dermatitis affecting 10-20% of children globally [2].

Disease	Estimated Global Prevalence (Millions)	Market Size (USD)	Growth Rate (CAGR, 2022–2028)
Ulcerative Colitis	1.3	$3.2 billion	6.2%
Crohn’s Disease	0.8	$2.5 billion	6.4%
Atopic Dermatitis	9.0	$7.4 billion	8.2%

2. Limitations of Existing Therapies

Current treatments, such as infliximab and vedolizumab, face challenges including immunogenicity, high costs, and delayed onset of action, leaving room for novel, oral, targeted therapies like Etrasimod.

3. Advantages of Etrasimod

• Oral administration enhances patient compliance
• Selective S1P receptor targeting reduces side effects
• Promising early-phase efficacy data provide optimism for clinical success

4. Competitive Landscape

Major competitors include:	Company	Lead Product	Mechanism	Indication	Approval Status	Key Differentiator
Bristol-Myers Squibb	Zeposia (ozanimod)	S1P receptor modulator	Multiple sclerosis, UC	Approved	Pan-indication potential
Gilead Sciences	Filgotinib	JAK inhibitor	Crohn’s, UC	Approved (Europe)	Different mechanism
Pfizer / Arena	Etrasimod	S1P receptor modulator	UC, Crohn’s, Atopic dermatitis	In development	Selectivity and safety profile

---

How Does Etrasimod Arginine Fit Into the Existing Market?

Market Positioning

• Innovator in Oral S1P Modulation: Distinguishes itself through receptor selectivity, potentially translating to a better safety profile.
• Addressing Unmet Needs: Potentially more effective or better tolerated than first-generation S1P modulators.
• Expanding Indications: Opportunities broaden across multiple immune-mediated conditions.

Strategic Partnerships & Commercialization

• Pfizer's global infrastructure accelerates market entry
• Potential collaborations with biotech firms for combination therapies
• Targeted marketing to gastroenterologists, dermatologists, and immunologists

---

What Are the Financial Projections and Revenue Outlook?

Revenue Projections (2023–2030)

Year	Estimated Revenue (USD Billion)	Key Assumptions
2023	$0.3	Regulatory filings underway, limited sales
2024	$0.8	Anticipated approval, initial market launch
2025	$1.5	Broader adoption, expanded indications
2026	$3.2	Peak sales, increased market penetration
2027+	$4.5+	Mature market, global expansion

Projection assumptions:

• Successful regulatory approval by 2024
• No significant safety issues reported
• Competitive landscape remains stable
• Pricing set within current market norms (~$50,000–$70,000 annually per patient) [3]

Cost Structure & Investment

Development Phase	Estimated Cost (USD Million)	Major Expenses
Preclinical & Phase 1	$100–150	Early safety, dosage studies
Phase 2	$200–300	Efficacy, larger cohorts
Phase 3	$300–500	Confirmatory trials, regulatory submission
Post-approval	$50–100 annually	Manufacturing, marketing

---

How Does the Regulatory Environment Influence the Market?

Regulatory Milestones

• FDA & EMA Approvals: Targeted for 2024–2025 based on ongoing trials.
• Conditional Approvals: Potential for accelerated pathways under breakthrough therapy designations.
• Post-market Surveillance: Critical for maintaining safety profile and patent protections.

Policy and Reimbursement

• Increasing push for oral therapies reduces hospitalization costs.
• Reimbursement trends favor innovation, especially in chronic disease management.
• Escalating drug prices could influence payer decisions, emphasizing value-based pricing.

---

What Are the Risks and Challenges?

Risk Factor	Impact	Mitigation Strategies
Clinical Failure	Revenue nullification	Diversify indications and combination therapies
Regulatory Delays	Market entry postponement	Early and continuous engagement with regulators
Competitive Pressure	Reduced market share	Differentiation via safety and efficacy
Pricing and Reimbursement	Revenue constraints	Early payer engagement, value demonstration

---

How Does Etrasimod Arginine Compare to Alternatives?

Attribute	Etrasimod Arginine	Zeposia (ozanimod)	Filgotinib	Existing Standard Therapies
Administration	Oral	Oral	Oral	IV/Injection (biologics)
Mechanism	S1P receptor selectivity	S1P receptor modulation	JAK inhibition	Varies
Indications	UC, Crohn's, Atopic dermatitis	Multiple sclerosis, UC	Crohn's	Moderate efficacy in some
Side Effects	Preliminary data promising	Bradycardia, infections	Infection risk	High immunogenicity, costs
Market Differentiator	High selectivity, safety	Approved, proven efficacy	Oral, effective	Established, but with limitations

---

FAQs

Q1: When is Etrasimod Arginine expected to reach the market?
Pending regulatory approval, anticipated in 2024–2025 based on ongoing trials and submissions.

Q2: What are the key benefits of Etrasimod over existing therapies?
Oral administration, high receptor selectivity, promising safety profile, and potential efficacy across multiple indications.

Q3: How large is the potential market for Etrasimod?
Targeting hundreds of millions worldwide, with initial revenues expected from a $3–4 billion global autoimmune therapies market.

Q4: What are the main competition hurdles?
Regulatory hurdles, clinical trial success, payer reimbursement, and competition from existing biologics and oral agents.

Q5: Are there any significant safety concerns with Etrasimod?
Clinical data so far suggests favorable safety, but comprehensive post-market surveillance will be critical.

---

Key Takeaways

• Growth Potential: Etrasimod Arginine stands at the cusp of entering a rapidly expanding immunomodulatory market, projected to reach over $16 billion globally by 2028.
• Differentiation: Its high selectivity and oral administration appeal to both clinicians and patients, potentially improving adherence and safety.
• Market Entry: Anticipated approval in the 2024–2025 window positions Pfizer to capitalize on unmet needs before top competitors launch similar agents.
• Risk Management: Clinical and regulatory success hinges on favorable trial outcomes and effective navigation of reimbursement complexities.
• Strategic Focus: Stakeholders should monitor ongoing trial data, regulatory developments, and competitive moves, tailoring strategies to optimize market penetration and profitability.

---

References

1. Arena Pharmaceuticals Clinical Trial Registry, 2023.
2. Global Autoimmune Disease Prevalence Data, WHO, 2022.
3. PharmMarket Insights, 2023.